RT Journal Article
SR Electronic
T1 The clinical and genetic spectrum of paediatric speech and language disorders in 52,143 individuals
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.23.24306192
DO 10.1101/2024.04.23.24306192
A1 Magielski, Jan
A1 Ruggiero, Sarah M.
A1 Xian, Julie
A1 Parthasarathy, Shridhar
A1 Galer, Peter
A1 Ganesan, Shiva
A1 Back, Amanda
A1 McKee, Jillian
A1 McSalley, Ian
A1 Gonzalez, Alexander K.
A1 Morgan, Angela
A1 Donaher, Joseph
A1 Helbig, Ingo
YR 2024
UL http://medrxiv.org/content/early/2024/04/23/2024.04.23.24306192.abstract
AB Speech and language disorders are known to have a substantial genetic contribution. Although frequently examined as components of other conditions, research on the genetic basis of linguistic differences as separate phenotypic subgroups has been limited so far.Here, we performed an in-depth characterization of speech and language disorders in 52,143 individuals, reconstructing clinical histories using a large-scale data mining approach of the Electronic Medical Records (EMR) from an entire large paediatric healthcare network.The reported frequency of these disorders was the highest between 2 and 5 years old and spanned a spectrum of twenty-six broad speech and language diagnoses. We used Natural Language Processing to assess to which degree clinical diagnosis in full-text notes were reflected in ICD-10 diagnosis codes. We found that aphasia and speech apraxia could be easily retrieved through ICD-10 diagnosis codes, while stuttering as a speech phenotype was only coded in 12% of individuals through appropriate ICD-10 codes. We found significant comorbidity of speech and language disorders in neurodevelopmental conditions (30.31%) and to a lesser degree with epilepsies (6.07%) and movement disorders (2.05%). The most common genetic disorders retrievable in our EMR analysis were STXBP1 (n=21), PTEN (n=20), and CACNA1A (n=18). When assessing associations of genetic diagnoses with specific linguistic phenotypes, we observed associations of STXBP1 and aphasia (P=8.57 x 10-7, CI=18.62-130.39) and MYO7A with speech and language development delay due to hearing loss (P=1.24 x 10-5, CI=17.46-Inf). Finally, in a sub-cohort of 726 individuals with whole exome sequencing data, we identified an enrichment of rare variants in synaptic protein and neuronal receptor pathways and associations of UQCRC1 with expressive aphasia and WASHC4 with abnormality of speech or vocalization.In summary, our study outlines the landscape of paediatric speech and language disorders, confirming the phenotypic complexity of linguistic traits and novel genotype-phenotype associations. Subgroups of paediatric speech and language disorders differ significantly with respect to the composition of monogenic aetiologies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementI.H. was supported by The Hartwell Foundation through an Individual Biomedical Research Award. This study received support from the National Institute for Neurological Disorders and Stroke (K02 NS112600); intramural funds of the Children's Hospital of Philadelphia from the Epilepsy NeuroGenetics Initiative (ENGIN); the EuroEPINOMICS-Rare Epilepsy Syndrome (RES) Consortium by the German Research Foundation (HE5415/3 1 to I.H.) within the EuroEPINOMICS framework of the European Science Foundation, by the German Research Foundation (DFG; HE5415/5 1; HE5415/6 1 to I.H.) by the DFG/FNR INTER Research Unit FOR2715 (We4896/4 570 1; and He5415/7 1 to I.H.) and by the Genomics Research and Innovation Network (GRIN grinnetwork.org).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Children's Hospital of Philadelphia gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes